Stock DNA
Pharmaceuticals & Biotechnology
USD 90 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.87
-107.75%
1.58
Total Returns (Price + Dividend) 
Shattuck Labs, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

Shattuck Labs Hits New 52-Week High of $2.71 Amid Market Challenges
Shattuck Labs, Inc. has achieved a new 52-week high of USD 2.71, rebounding from a low of USD 0.69. Despite this milestone, the company has experienced a significant decline in performance over the past year, with a market capitalization of approximately USD 90 million and ongoing financial challenges.
Read More
Shattuck Labs, Inc. Hits New 52-Week High at $2.64
Shattuck Labs, Inc. has achieved a new 52-week high of USD 2.64, marking a significant recovery from its previous low of USD 0.69. Despite this milestone, the company has experienced a 61.34% decline over the past year and remains loss-making, with a market capitalization of approximately USD 90 million.
Read More
Shattuck Labs Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
Shattuck Labs, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. While the stock has faced a challenging year, it has shown resilience with a notable year-to-date increase. Technical indicators present a mixed outlook, suggesting cautious optimism as the company navigates the biotechnology sector.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 20 Schemes (13.44%)
Held by 28 Foreign Institutions (5.64%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is -100.00% vs 700.00% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 42.13% vs -1.41% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 235.29% vs 142.86% in Dec 2023
YoY Growth in year ended Dec 2024 is 13.63% vs 14.33% in Dec 2023






